Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Novavax's latest COVID-19 vaccine delay sends shares tumbling nearly 20%
Kaiser Permanente, Ascension Health and 86 other health systems requiring mandatory COVID-19 vaccines for their workforces
Moderna is ready to spend billions in COVID-19 cash, and the famed biotech has sights set on gene editing
COVID-19 tracker: J&J shot protects against severe Delta cases; FDA working quickly on booster plans
Telehealth provider Cadence debuts with $41M to bring hospital care home
Illumina posts 78% revenue growth as cancer, DNA testing ramp back up

Featured Story

Novavax's latest COVID-19 vaccine delay sends shares tumbling nearly 20%

By Kyle LaHucik

Novavax hit another roadblock in its COVID-19 vaccine journey in the U.S., with the company pushing back an FDA filing from May to July to now the fourth quarter. The company filed in India, Indonesia and the Philippines this week, and expects more submissions later this year with WHO, UK, EU, Australia, Canada and New Zealand.

Kaiser Permanente, Ascension Health and 86 other health systems requiring mandatory COVID-19 vaccines for their workforces

By Dave Muoio

COVID-19 vaccination as a condition of employment has picked up the support of numerous industry and professional organizations. More health systems are taking a hard stance.

Moderna is ready to spend billions in COVID-19 cash, and the famed biotech has sights set on gene editing

By Annalee Armstrong

Moderna has found a direction to volley its mountain of COVID-19 vaccine cash: gene editing. Executives revealed during a second-quarter earnings call Thursday that Moderna is ready to “expand our horizons” with external technologies or products. Read: They’re ready to start buying.

COVID-19 tracker: J&J shot protects against severe Delta cases; FDA working quickly on booster plans

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

In a large trial in South Africa, Johnson & Johnson's vaccine protected healthcare workers from severe disease associated with the troublesome Delta variant. Meanwhile, the FDA is working quickly to develop its plans on COVID-19 vaccine boosters. Plus more headlines.

Telehealth provider Cadence debuts with $41M to bring hospital care home

By Conor Hale

With the emergency of the COVID-19 pandemic illustrating telehealth's benefits, a new company called Cadence hopes to keep hospitals moving to the beat of the same drum.

Illumina posts 78% revenue growth as cancer, DNA testing ramp back up